首页> 外文OA文献 >Proteomics-Based Identification of Anchorless Cell Wall Proteins as Vaccine Candidates against Staphylococcus aureus▿ †
【2h】

Proteomics-Based Identification of Anchorless Cell Wall Proteins as Vaccine Candidates against Staphylococcus aureus▿ †

机译:基于蛋白质组学的无锚细胞壁蛋白鉴定为金黄色葡萄球菌的疫苗候选者

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Staphylococcus aureus is an important human pathogen with increasing clinical impact due to the extensive spread of antibiotic-resistant strains. Therefore, development of a protective polyvalent vaccine is of great clinical interest. We employed an intravenous immunoglobulin (IVIG) preparation as a source of antibodies directed against anchorless S. aureus surface proteins for identification of novel vaccine candidates. In order to identify such proteins, subtractive proteome analysis (SUPRA) of S. aureus anchorless cell wall proteins was performed. Proteins reacting with IVIG but not with IVIG depleted of S. aureus-specific opsonizing antibodies were considered vaccine candidates. Nearly 40 proteins were identified by this preselection method using matrix-assisted laser desorption ionization—time of flight analysis. Three of these candidate proteins, enolase (Eno), oxoacyl reductase (Oxo), and hypothetical protein hp2160, were expressed as glutathione S-transferase fusion proteins, purified, and used for enrichment of corresponding immunoglobulin Gs from IVIG by affinity chromatography. Use of affinity-purified anti-Eno, anti-Oxo, and anti-hp2160 antibodies resulted in opsonization, phagocytosis, and killing of S. aureus by human neutrophils. High specific antibody titers were detected in mice immunized with recombinant antigens. In mice challenged with bioluminescent S. aureus, reduced staphylococcal spread was measured by in vivo imaging. The recovery of S. aureus CFU from organs of immunized mice was diminished 10- to 100-fold. Finally, mice immunized with hp2160 displayed statistically significant higher survival rates after lethal challenge with clinically relevant S. aureus strains. Taken together, our data suggest that anchorless cell wall proteins might be promising vaccine candidates and that SUPRA is a valuable tool for their identification.
机译:金黄色葡萄球菌是重要的人类病原体,由于抗生素耐药菌株的广泛传播,其临床影响日益增加。因此,开发保护性多价疫苗具有很大的临床意义。我们采用了静脉免疫球蛋白(IVIG)制剂作为针对无锚金黄色葡萄球菌表面蛋白的抗体来源,用于鉴定新型疫苗候选物。为了鉴定此类蛋白质,进行了金黄色葡萄球菌无锚细胞壁蛋白质的减性蛋白质组分析(SUPRA)。与IVIG反应但不与IVIG反应的蛋白质被消耗了金黄色葡萄球菌特异性调理抗体,因此被认为是候选疫苗。通过这种预选方法,使用基质辅助激光解吸电离-飞行时间分析,鉴定出近40种蛋白质。这些候选蛋白中的三个,烯醇酶(Eno),氧酰还原酶(Oxo)和假定蛋白hp2160,被表达为谷胱甘肽S-转移酶融合蛋白,经过纯化,并用于通过亲和色谱法从IVIG富集相应的免疫球蛋白Gs。使用亲和纯化的抗Eno,抗Oxo和抗hp2160抗体可导致调理作用,吞噬作用以及人嗜中性粒细胞杀死金黄色葡萄球菌。在用重组抗原免疫的小鼠中检测到高特异性抗体滴度。在用生物发光金黄色葡萄球菌攻击的小鼠中,通过体内成像测量了葡萄球菌传播减少。从免疫小鼠器官中回收金黄色葡萄球菌CFU减少了10到100倍。最后,用hp2160免疫的小鼠在临床相关的金黄色葡萄球菌致死性攻击后显示出较高的存活率。综上所述,我们的数据表明无锚细胞壁蛋白可能是有前途的候选疫苗,而SUPRA是鉴定它们的宝贵工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号